First Trust NYSE Arca Biotechnology Index Fund
220 hedge funds and large institutions have $663M invested in First Trust NYSE Arca Biotechnology Index Fund in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 96 reducing their positions, and 47 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
2.19% less ownership
Funds ownership: 47.03% → 44.84% (-2.2%)
11% less funds holding
Funds holding: 247 → 220 (-27)
17% less capital invested
Capital invested by funds: $801M → $663M (-$138M)
51% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 47
53% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 96
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$4.33M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.16M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$3.04M |
| 4 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
+$1.91M |
| 5 |
IAA
Independent Advisor Alliance
Charlotte,
North Carolina
|
+$1.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$15.3M |
| 2 |
BWM
Bulltick Wealth Management
Miami,
Florida
|
-$12.9M |
| 3 |
KCM
Karp Capital Management
Sausalito,
California
|
-$12.1M |
| 4 |
LPL Financial
San Diego,
California
|
-$8.51M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6.64M |
FBT Hedge Fund Activity: Q1 2022 in Review
220 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q1 2022, worth a combined $663M — down 17% from $801M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of FBT and 23 opened new positions — a net loss of 24 holders — while 96 trimmed existing stakes and 45 added.
The largest buyer was Old Mission Capital, opening a new position worth an estimated $4.33M. The largest seller was Morgan Stanley, cutting an estimated $15.3M.
- 220 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q1 2022, down from 247 in Q4 2021.
- Funds reported $663M of First Trust NYSE Arca Biotechnology Index Fund stock for Q1 2022, down 17% quarter-over-quarter.
- 23 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q1 2022 and 47 closed out, a net change of -24 holders.
- The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q1 2022 was Old Mission Capital, an estimated $4.33M added.
- The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q1 2022 was Morgan Stanley, an estimated $15.3M sold.
Based on aggregated 13F filings for Q1 2022.